Zimmer Biomet Supply Woes Could Leave An Opening In Joint Markets
Executive Summary
Zimmer Biomet said it was not able to maintain supply to meet strong demand for its hip, knee and other joint products that grew out of cross-selling opportunities. As a result, the firm fell short of financial expectations in Q3. The company said it is working to improve its supply-chain procedures, but there could be a short-term chance for competitors to make some gains, analysts suggest.
You may also be interested in...
Zimmer Biomet Buys LDR To Boost Spine Revenue Growth
The world's second-largest orthopedic device firm, Zimmer Biomet, is making its biggest move since Zimmer and Biomet merged in 2015 with a $1 billion acquisition of spine-device specialists LDR.
FDA Eyes Upclassification, Labeling Guidance To Address Stapler Risks
The US agency sent a letter to health-care providers spotlighting its analysis of the increasing numbers of adverse events linked to surgical staplers and implantable staples, and its plans for a draft guidance on labeling and an advisory panel meeting to consider a 510(k) requirement for the products.
Device Week, March 8, 2019 – Scott Gottlieb Resigns
On the latest Medtech Insight podcast, David Filmore and Ferdous Al-Faruque discuss the unexpected news that Scott Gottlieb is leaving US FDA next month. What has been his legacy for medtech, and who will replace him?